

40. Tezol O, Citak EC, Ayhan YS et al. Effective High-dose Interferon- α Therapy in a 13-Year-Old Girl With Erdheim-Chester Disease. *J Pediatr Hematol Oncol* 2019. doi: 10.1097/MPH.0000000000001538.
41. Aouba A, Georgin-Laviolle S, Pagnoux C et al. Rationale and efficacy of interleukin-1 targeting in Erdheim-Chester disease. *Blood* 2010; 116(20): 4070–4076.
42. Podestà MA, Graziani G, Reggiani F et al. Improvement of Erdheim-Chester disease-related renal failure after treatment with anakinra. *Kidney Res Clin Pract* 2014; 33(3): 165–167.
43. Szturz P, Adam Z, Rehák Z et al. Xanthelasma palpebrarum responding to interleukin-1 blockade. *Intern Med J* 2014; 44(6): 617–618.
44. Darstein F, Kirschev S, Heckl S et al. Successful treatment of Erdheim-Chester disease with combination of interleukin-1-targeting drugs and high-dose glucocorticoids. *Intern Med J* 2014; 44(1): 90–92.
45. Courcoul A, Vignot E, Chapurlat R. Successful treatment of Erdheim-Chester disease by interleukin-1 receptor antagonist protein. *Joint Bone Spine* 2014; 81(2): 175–177.
46. Killu AM, Liang JJ, Jaffe AS. Erdheim-Chester disease with cardiac involvement successfully treated with anakinra. *Int J Cardiol* 2013; 167(5): e115–117.
47. Aubert O, Aouba A, Deshayes S et al. Favorable radiological outcome of skeletal Erdheim-Chester disease involvement with anakinra. *Joint Bone Spine* 2013; 80(2): 206–207.
48. Tran TA, Pariente D, Lecron JC et al. Treatment of pediatric Erdheim-Chester disease with interleukin-1-targeting drugs. *Arthritis Rheum* 2011; 63(12): 4031–4032.
49. Cohen-Aubart F, Maksud P, Saadoun D et al. Variability in the efficacy of the IL1 receptor antagonist anakinra for treating Erdheim-Chester disease. *Blood* 2016; 127(11): 1509–1512.
50. Goyal G, Shah MV, Call TG et al. Efficacy of biological agents in the treatment of Erdheim-Chester disease. *Br J Haematol*. 2018; 183: 520–524.
51. Franconieri F, Deshayes S, de Boysson H et al. Superior efficacy and similar safety of double dose anakinra in Erdheim-Chester disease after single dose treatment. *Oncimmunology* 2018; 7(8): e1450712. doi: 10.1080/2162402X.2018.1450712.
52. Dagna L, Corti A, Langheim S et al. Tumor necrosis factor α as a master regulator of inflammation in Erdheim-Chester disease: rationale for the treatment of patients with infliximab. *J Clin Oncol* 2012; 30(28): e286–e290.
53. Ferrero E, Belloni D, Corti A et al. TNF- α in Erdheim-Chester disease pericardial effusion promotes endothelial leakage in vitro and is neutralized by infliximab. *Rheumatology (Oxford)*. 2014; 53(1): 198–200.
54. Goyal G, Shah MV, Call TG et al. Efficacy of biological agents in the treatment of Erdheim-Chester disease. *Br J Haematol* 2018; 183(3): 520–524.
55. Cohen-Aubart F, Maksud P, Emile J-F et al. Efficacy of infliximab in the treatment of Erdheim-Chester disease. *Ann Rheum Dis* 2018; 77: 1387–1390.
56. Jia X, Ning X, Bai Q et al. Combination of adalimumab with lower dose of methylprednisolone in Erdheim-Chester disease with systemic involvement. *Acta Oncol*. 2017; 56(5): 753–756.
57. Haroche J, Amoura Z, Charlotte F et al. Imatinib mesylate for platelet-derived growth factor receptor-beta-positive Erdheim-Chester histiocytosis. *Blood* 2008; 111(11): 5413–5415.
58. Montella L, Insabato L, Palmieri G. Imatinib mesylate for cerebral Langerhans'-cell histiocytosis. *N Engl J Med* 2004; 351(10): 1034–1035.
59. Utikal J, Ugurel S, Kurzen H et al. Imatinib as a treatment option for systemic non-Langerhans cell histiocytoses. *Arch Dermatol* 2007; 143(6): 736–740.
60. Haroche J, Charlotte F, Arnaud L et al. High prevalence of BRAF V600E mutations in Erdheim-Chester disease but not in other non-Langerhans cell histiocytoses. *Blood* 2012; 120(13): 2700–2703.
61. Haroche J, Cohen-Aubart F, Emile JF et al. Dramatic efficacy of vemurafenib in both multisystemic and refractory Erdheim-Chester disease and Langerhans cell histiocytosis harboring the BRAF V600E mutation. *Blood* 2013; 121(9): 1495–1500.
62. Hyman DM, Puzanov I, Subbiah V et al. Vemurafenib in multiple nonmelanoma cancers with BRAF V600 mutations. *N Engl J Med* 2015; 373: 726–736.
63. Diamond EL, Durham BH, Haroche J et al. Diverse and targetable kinase alterations drive histiocytic neoplasms. *Cancer Discov* 2016; 6: 154–165.
64. Emile J-F, Diamond EL, Hélias-Rodzewicz Z et al. Recurrent RAS and PIK3CA mutations in Erdheim-Chester disease. *Blood* 2014; 124: 3016–3019.
65. Cohen-Aubart F, Emile JF, Maksud P et al. Marked efficacy of vemurafenib in suprasellar Erdheim-Chester disease. *Neurology* 2014; 83(14): 1294–1296.
66. Diamond EL, Durham BH, Ulaner GA et al. Efficacy of MEK inhibition in patients with histiocytic neoplasms. *Nature* 2019; 567: 521–524.
67. Euskirchen P, Haroche J, Emile JF et al. Complete remission of critical neurohistiocytosis by vemurafenib. *Neurol Neuroimmunol Neuroinflamm* 2015; 2(2): e78.
68. Franconieri F, Martin-Silva N, de Boysson H et al. A. Superior efficacy and tolerance of reduced doses of vemurafenib plus anakinra in Erdheim-Chester disease: Towards the paradigm of combined targeting and immune therapies. *Acta Oncol Acta Oncol*. 2016; 55(7): 930–930.
69. Haroche J, Cohen-Aubart F, Emile JF et al. Reproducible and sustained efficacy of targeted therapy with vemurafenib in patients with BRAF(V600E)-mutated Erdheim-Chester disease. *J Clin Oncol* 2015; 33(5): 411–4118.
70. Schirmer JH, Thorns C, Moosig F et al. Treatment failure by canakinumab in a patient with progressive multisystemic Erdheim-Chester disease refractory to anakinra: successful use of vemurafenib. *Rheumatology (Oxford)* 2015; 54(10): 1932–1934.
71. Tzoulis C, Schwarzlmüller T, Gjerde IO et al. Excellent response of intramedullary Erdheim-Chester disease to vemurafenib: a case report. *BMC Res Notes* 2015; 8: 171.
72. Oneal PA, Kwitkowski V, Luo L et al. FDA Approval Summary: Vemurafenib for the Treatment of Patients with Erdheim-Chester Disease with the BRAFV600 Mutation. *Oncologist*. 2018; 23(12): 1520–1524.
73. Diamond EL, Subbiah V, Lockhart AC et al. Vemurafenib for BRAF V600-mutant Erdheim-Chester disease and Langerhans cell histiocytosis: analysis of data from the histology-independent, phase 2, open-label VE-BASKET study. *JAMA Oncol*. 2018; 4: 384–388.
74. Cohen Aubart F, Emile J-F, Carrat F et al. Targeted therapies in 54 patients with Erdheim-Chester disease, including follow-up after interruption (the LOVE study). *Blood* 2017; 130: 1377–1380.
75. Bhatia A, Hatzoglu V, Ulaner G et al. Neurologic and oncologic features of Erdheim-Chester disease: a 30-patient series. *Neuro Oncol* 2020 Jan 17. pii: noaa008. doi: 10.1093/neuonc/noaa008.
76. Grob JJ, Amonkar MM, Karaszewska B. Comparison of dabrafenib and trametinib combination therapy with vemurafenib monotherapy on health-related quality of life in patients with unresectable or metastatic cutaneous BRAF Val600-mutation-positive melanoma (COMBI-v): results of a phase 3, open-label, randomised trial. *Lancet Oncol* 2015; 16(13): 1389–1398.
77. Al Bayati A, Plate T, Al Bayati M et al. Dabrafenib and Trametinib Treatment for Erdheim-Chester Disease With Brain Stem Involvement. *Mayo Clin Proc Innov Qual Outcomes*. 2018; 2(3): 303–308.
78. Sanders IM, Goodman A, Kurzrock R. Real world toxicity experience with BRAF/MEK inhibitors in patients with Erdheim-Chester disease. *The Oncologist* 2019; 24: 1–5.
79. Campochiaro C, Cavalli G, Farina N et al. Efficacy and improved tolerability of combination therapy with interleukin-1 blockade and MAPK pathway inhibitors for the treatment of Erdheim-Chester disease. *Ann Rheum Dis*. 2019 Dec 9. pii: annrheumdis-2019-216610. doi: 10.1136/annrheumdis-2019-216610
80. Fernández-Eulate G, Muñoz-Lopetegui A, Ruiz I et al. Vemurafenib as first-line therapy in BRAF-V600E-mutant Erdheim-Chester disease with CNS involvement. *BMJ Case Rep* 2019; 12(11). pii: e228280. doi: 10.1136/bcr-2018-228280.
81. Van Keerberghen CA, Harrouk A, Leone L. A new role for fluorine-18-fluorodeoxyglucose positron-emission tomography/computed tomography in Erdheim-Chester disease. *World J Nucl Med*. 2019; 18(2): 201–203.
82. Akin EA, Osman M, Ellenbogen AL. FDG PET/CT Findings of Erdheim-Chester Disease: Radiologic Response to a Novel Treatment Regimen. *Clin Nucl Med*. 2018; 43(5): 337–340.
83. Young JR, Johnson GB, Murphy RC et al. (18)F-FDG PET/CT in Erdheim-Chester Disease: Imaging Findings and Potential BRAF Mutation Biomarker. *J Nucl Med*. 2018; 59(5): 774–779.
84. Rehák Z, Koukalová R, Vašina J et al. 18F-FDG PET/CT obraz Erdheimovy-Chesterovy nemoci – přehled českých pacientů. *Nucl. Med*. 20; 7: 50–56.